leadf
logo-loader
viewNaturally Splendid Enterprises Ltd.
(
TSX-V:NSPOTC:NSPDF
)

Naturally Splendid Enterprises greenlit to begin Phase 2 study for its potential COVID-19 treatment

Biologic Pharmamedical CEO Franco Cavaleri tells Proactive the group, together with Naturally Splendid Enterprises Ltd (CVE:NSP) (OTCQB:NSPDF) has received a Notice of Authorization from Health Canada to proceed with a Phase 2 clinical trial for a potential COVID-19 treatment utilizing the target drug Cavaltinib. Cavaleri says within 60-90 days the company should be able to begin the trial. Cavaleri says he hopes Cavaltinib will show positive results in mitigating the 'cytokine storm' with COVID-19 patients

Quick facts: Naturally Splendid Enterprises Ltd.

Follow
TSX-V:NSP

Price: 0.045 CAD

Market Cap: $9.81 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Naturally Splendid’s Natera Plant-based products will offer select products...

Naturally Splendid CEO Craig Goodwin joined Steve Darling from Proactive to share details that the company’s test run with Denny’s Restaurant has gone well and now a select number of their products will now be featured at 71 Denny's across Canada starting later this fall. Goodwin also told...

4 weeks, 1 day ago

2 min read